JUNSHI BIO (688180.SH): Tuoyi adds indications and Junshida included in the national medical insurance directory.

JUNSHI BIO (688180.SH) announced that its two products, Toripalimab Injection (trade name: Tuoyi, product code: JS001) and Camrelizumab Injection (trade name: Junshida, product code: JS002), have been included in the Category B of the "National Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance Drug List (2025)" (hereinafter referred to as the "National Medical Insurance List"). The new version of the National Medical Insurance List will officially come into effect on January 1, 2026. As of the date of this announcement, the company's four commercial products, Tuoyi, Atezolizumab Injection (trade name: Junmaikang, product code: UBP1211), Deuterium bromide toripalimab tablet (trade name: Mindewei, product code: VV116/JT001), and Junshida, have all been included in the National Medical Insurance List. Tuoyi has all its 12 approved indications for marketing in mainland China included in the National Medical Insurance List, making it the only anti-PD-1 monoclonal antibody drug for the treatment of renal cancer, triple-negative breast cancer, and melanoma in the list; Junshida is included for the first time, being the only domestically produced PCSK9 target drug for statin-intolerant population in the new version of the list.